<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two studies in this issue identify the landscape of <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and highlight the pathogenic and clinical relevance of inactivating mutations of ID3, an inhibitor of the TCF3 transcription factor </plain></SENT>
</text></document>